PURPOSE: Advance care planning (ACP) in hematopoietic stem-cell transplantation (HSCT) is challenging, given the potential for cure despite increased morbidity and mortality risk.The aim of this study was to evaluate ACP and palliative care (PC) integration for patients who underwent HSCT. METHODS: A retrospective analysis was conducted and data were extracted from electronic medical records of patients who underwent HSCT between January 2011 and December 2015. Patients who received more than one transplant and who were younger than 18 years of age were excluded. The primary objective was to determine the setting and specialty of the clinician who documented the initial and final code status. Secondary objectives included evaluation of advance directive and/or completion of the Physician Orders for Life-Sustaining Treatment form, PC consultation, hospice enrollment, and location of death. RESULTS: The study sample comprised 39% (n = 235) allogeneic and 61% (n = 367) autologous HSCTs. All patients except one (n = 601) had code status documentation, and 99.2% (n = 596) were initially documented as full code. Initial and final code status documentation in the outpatient setting was 3% (n = 17) and 24% (n = 143), respectively. PC consultation occurred for 19% (n = 114) of HSCT patients, with 83% (n = 95) occurring in the hospital. Allogeneic transplant type and age were significantly associated with greater rates of advance directive and/or Physician Orders for Life-Sustaining Treatment completion. Most patients (85%, n = 99) died in the hospital, and few were enrolled in hospice (15%, n = 17). CONCLUSION: To our knowledge, this is the largest single-center study of ACP and PC integration for patients who underwent HSCT. Code status documentation in the outpatient setting was low, as well as utilization of PC and hospice services.
PURPOSE: Advance care planning (ACP) in hematopoietic stem-cell transplantation (HSCT) is challenging, given the potential for cure despite increased morbidity and mortality risk.The aim of this study was to evaluate ACP and palliative care (PC) integration for patients who underwent HSCT. METHODS: A retrospective analysis was conducted and data were extracted from electronic medical records of patients who underwent HSCT between January 2011 and December 2015. Patients who received more than one transplant and who were younger than 18 years of age were excluded. The primary objective was to determine the setting and specialty of the clinician who documented the initial and final code status. Secondary objectives included evaluation of advance directive and/or completion of the Physician Orders for Life-Sustaining Treatment form, PC consultation, hospice enrollment, and location of death. RESULTS: The study sample comprised 39% (n = 235) allogeneic and 61% (n = 367) autologous HSCTs. All patients except one (n = 601) had code status documentation, and 99.2% (n = 596) were initially documented as full code. Initial and final code status documentation in the outpatient setting was 3% (n = 17) and 24% (n = 143), respectively. PC consultation occurred for 19% (n = 114) of HSCT patients, with 83% (n = 95) occurring in the hospital. Allogeneic transplant type and age were significantly associated with greater rates of advance directive and/or Physician Orders for Life-Sustaining Treatment completion. Most patients (85%, n = 99) died in the hospital, and few were enrolled in hospice (15%, n = 17). CONCLUSION: To our knowledge, this is the largest single-center study of ACP and PC integration for patients who underwent HSCT. Code status documentation in the outpatient setting was low, as well as utilization of PC and hospice services.
Authors: Richard J Lin; Abigail G Cohen; Stacy M Stabler; Sean M Devlin; Theresa A Elko; Molly A Maloy; Beatriz Korc-Grodzicki; Koshy Alexander; Dana Kramer; Míriam Sanchez-Escamilla; Nerea Castillo Flores; Juliet N Barker; Christina Cho; Parastoo B Dahi; Boglarka Gyurkocza; Esperanza B Papadopoulos; Miguel-Angel Perales; Ioannis Politikos; Doris M Ponce; Craig S Sauter; Michael Scordo; Brian C Shaffer; Gunjan L Shah; Roni Tamari; James W Young; Ann A Jakubowski; Sergio A Giralt; Judith E Nelson Journal: J Palliat Med Date: 2020-03-27 Impact factor: 2.947
Authors: Winnie S Wang; Joseph D Ma; Sandahl H Nelson; Carolyn Revta; Gary T Buckholz; Carolyn Mulroney; Eric J Roeland Journal: Support Care Cancer Date: 2017-12-28 Impact factor: 3.603
Authors: Joseph D Ma; Alexandra Dullea; Chelsea Hagmann; Sarah Friedman; Michelle Russell; Arlene Cramer; Melanie Benn; Eric J Roeland Journal: JCO Oncol Pract Date: 2021-01-08
Authors: Steffen T Simon; Anne Pralong; Michael Hallek; Christoph Scheid; Udo Holtick; Marco Herling Journal: Ann Hematol Date: 2021-05-06 Impact factor: 3.673
Authors: Jorge Garcia Borrega; Jan-Michel Heger; Matthias Kochanek; Dennis A Eichenauer; Philipp Koehler; Udo Holtick; Michael Hallek; Christof Scheid; Boris Böll; Alexander Shimabukuro-Vornhagen Journal: Ann Hematol Date: 2021-10-20 Impact factor: 3.673